[9] [10] Classification [edit] Protein sequence and structure are important additional classification criteria for the three superfamilies (cytosolic, mitochondrial, and MAPEG) of GSTs: while classes from the cytosolic superfamily of GSTs possess more than 40% sequence homology, those from other classes may have less than 25%

Common causes: MTHFR gene mutations (C677T, A1298C) reducing enzyme efficiency Vitamin B deficiencies (folate, B12, B6) preventing homocysteine recycling Kidney disease impairing homocysteine clearance Certain medications (methotrexate, antacids, metformin) Hypothyroidism Aging Health risks associated with high homocysteine: Cardiovascular disease damages blood vessel walls, promotes atherosclerosis Blood clots increases risk of DVT, pulmonary embolism, stroke Heart attack and stroke particularly when levels exceed 15 mol/L Pregnancy complications miscarriage, preeclampsia, neural tube defects Cognitive decline Alzheimers disease, dementia, memory problems Osteoporosis weakens bone structure Depression and mental health issues Treatment approach: Increase methylated B vitamins (methylfolate, methyl-B12, B6) Improve diet with folate-rich foods Address underlying deficiencies Support methylation pathways Monitor and reduce levels to optimal range (below 10 mol/L) The goal: Lower homocysteine by improving your bodys ability to process it efficiently

American Journal on Addictions 20: 441-446
Biosharp) according to standard protocols
High oxygen affinity hemoglobins
Injectable protocols using 1-2 mg daily typically show subtle scalp health improvements at 4-8 weeks, visible thickness and density changes at 12-16 weeks, and optimal results at 6+ months